Weight-Loss Medications Linked to a Rare Eye Condition Causing Sudden Vision Loss: Study - Video

Could popular diabetes and weight-loss medications increase the risk of sudden vision loss? A new study suggests that glucagon-like peptide-1 (GLP-1) medications may be associated with a small but potentially serious risk of ischemic optic neuropathy, a rare condition that can cause permanent visual impairment.

Published in Annals of Internal Medicine, the study led by researchers at Rutgers University examined health records of US adults aged 18 to 65 years with type 2 diabetes who had recently started medications for managing their condition.

The investigation focused on GLP-1-based therapies. These medications are widely used for blood glucose control and weight management and have demonstrated cardiovascular and kidney benefits in selected patients.

Researchers found that GLP-1 medication use was associated with a modest increase in ischemic optic neuropathy, a condition caused by insufficient blood supply to the optic nerve.

Although the condition remained rare, the study estimated approximately three to four additional cases per 10,000 patients treated over 18 months.

The analysis also revealed that cases were more frequently observed among men and adults aged 50 to 65 years.

Ischemic optic neuropathy can cause sudden blurring, dimming or missing areas of vision, usually affecting one eye. Vision loss may be permanent, although some patients experience partial recovery.

Researchers emphasised that the findings demonstrate an association rather than proving that GLP-1 medications directly cause optic nerve damage. Underlying health conditions and other patient characteristics may contribute to the observed risk.

Despite the potential concern, the absolute risk remains low, and these medications provide established benefits for many patients.

The findings highlight the importance of continued medication safety monitoring and prompt ophthalmological evaluation for patients experiencing sudden visual changes during treatment.

REFERENCE: Kamika R. Reynolds, Kimberly M. O’Malley, Jason A. Roy, Chintan V. Dave. Glucagon-like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy. Annals of Internal Medicine, 2026; 179 (9): 1244 DOI: 10.7326/ANNALS-25-00860